🇺🇸 FDA
Patent

US 12365729

Anti-hemojuvelin (HJV) antibodies for treating myelofibrosis

granted A61KA61K2039/505A61P

Quick answer

US patent 12365729 (Anti-hemojuvelin (HJV) antibodies for treating myelofibrosis) held by Disc Medicine, Inc. expires Mon Jul 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Disc Medicine, Inc.
Grant date
Tue Jul 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
30
CPC classes
A61K, A61K2039/505, A61P, A61P35/00, A61P7/06